Life Science Intelligence

Under the direction of CEO Tyler Zanon, EndoShunt Medical is developing a minimally invasive endovascular shunting device designed to give trauma surgeons temporary, targeted control over abdominal blood flow while maintaining perfusion to the rest of the body. In the most severe hemorrhage cases, where every minute can shape both survival and long-term quality of life, EndoShunt is working to replace blunt tools with a more controlled approach. As Zanon put it, “EndoShunt gives trauma surgeons the gift of time, so they can give trauma patients the gift of life.” Origin Story For Zanon, the mission behind EndoShunt is closely tied to the realities of trauma care. Based in Chicago, he has spent roughly 15 years in healthcare product development, first in academia and then in industry. Living in a major city with high rates of traumatic injury, he has seen how urgent the problem remains. “We haven’t seen actual innovation since World War II,” Zanon said. He often explains the challenge w...

Over the past several weeks, acquisition announcements have arrived at a rapid pace across the industry. Between transactions involving Medtronic, ResMed, Artivion, and Roche, nearly $2 billion in deal value has been announced in a short period of time. The headlines naturally raise a question: are we witnessing a true surge in medtech M&A , or are a handful of high-profile deals creating that impression? A review of recent transactions, combined with activity tracked in Compass AI , suggests that strategic buyers remain highly active. However, the broader data indicate a market that is accelerating within an established trend rather than entering entirely new territory. The Same Acquisition Playbook Continues to Win Although the companies and technologies differ, the latest transactions share several common characteristics. Strategic acquirers continue to target businesses with commercial traction, attractive growth profiles, and technologies that strengthen existing franchises. R...

Siemens Healthineers sits among the largest companies in medtech. With approximately $25 billion in revenue in 2025, the company operates at a scale comparable to some of the industry’s biggest names and continues to invest heavily in markets where it sees long-term growth potential. A series of partnership announcements over the past year offers a window into where Siemens Healthineers appears to be investing for the future. Across robotics, AI, diagnostics software, and health system infrastructure, Siemens Healthineers has assembled a network of relationships that increasingly points toward one destination: neuro. Viewed individually, each agreement serves a specific purpose. Taken together, they suggest a broader strategy centered on neuroimaging, precision therapy, and integrated clinical workflows. A Company Becoming More Focused Siemens AG announced plans to deconsolidate its majority stake in Siemens Healthineers, a process that has been underway for some time. For Healthineers...

With Q2 already underway, the latest medtech Q1 earnings reports offer an early read on where major strategics are gaining momentum, where pressure is building, and what strategic priorities are becoming clearer. This quarter’s results point to a consistent theme: focused portfolios are outperforming broader platforms. Companies concentrated in clearly defined growth markets, particularly cardiovascular/structural heart, are delivering stronger execution. More diversified players remain highly competitive, but they are managing a wider mix of operational, integration, and macroeconomic challenges. A closer look at the numbers makes that trend difficult to ignore. Focused Players Continue to Separate Themselves Abbott delivered $5.5 billion in Q1 Medical Devices revenue, representing 8.5% organic growth and 13.2% reported growth year over year. Electrophysiology, Rhythm Management, and Heart Failure each posted double-digit gains, while the U.S. launch of Volt supported EP performance. ...